Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, PhD, Gerald Wulf, MD, Lorenz Truemper, MD, Francesco d'Amore, MD, Thomas Relander, Helle Toldbod, MS,PhD, Jan M.A. Delabie, MD PhD, Andreas Rosenwald, Marita Ziepert, PhD, Markus Loeffler, MD

Blood (2018) 132 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2018-99-112076

Published: 2018

Journal Articles

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Blood (2017) 130 (Supplement 1): 822.

https://doi.org/10.1182/blood.V130.Suppl_1.822.822

Published: 2017

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Hanne Kuitunen, Helle Toldbod, Lone Bredo Pedersen, Christian Winther Eskelund, Kirsten Grønbæk, Carsten Utoft Niemann, Christian H Geisler, Arne Kolstad

Blood (2016) 128 (22): 148.

https://doi.org/10.1182/blood.V128.22.148.148

Published: 2016

Journal Articles

Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study

Fredrik Ellin, MD PhD, Knut Liestøl, Susanna Mannisto, Grete F Lauritzsen, MD, Esa Jantunen, MD PhD, Peter A Meyer, Helle Toldbod, Thomas Relander, MD PhD, Francesco A d'Amore, MD

Blood (2016) 128 (22): 1830.

https://doi.org/10.1182/blood.V128.22.1830.1830

Published: 2016

Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod

Blood (2014) 124 (21): 5435.

https://doi.org/10.1182/blood.V124.21.5435.5435

Published: 2014

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Blood (2011) 118 (21): 331.

https://doi.org/10.1182/blood.V118.21.331.331

Published: 2011

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

NARROW

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only